Urinary triaosylceramide (Gb3) as a marker of cardiac disease
OwnerRaphael Schiffmann, Fanny Mochel +2inventors
InventorsRaphael Schiffmann, Fanny Mochel, Lawrence Sweetman, Sabrina Forni
Life of this patent
Estimating the term…
Abstract
The present invention describes a method for determination of urinary globotriaosylceramide (Gb3) levels in non-Fabry disease cardiac patients. Determination of Gb3 levels provides a screening method for determining cardiac risk and may offer an alternative therapeutic option for cardiac disease management or cardiac disease risk mitigation by lowering Gb3 levels by the use of pharmacological chaperones or other agents.
Claims7
A method of treating a cardiac disease or condition in a non-Fabry disease subject comprising administering to the subject in need thereof an effective amount of 1-deoxygalactonojirimycin or a salt thereof, wherein the subject does not have Fabry disease.
Dependencies are inferred from the claim text.